Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.
All News
Autoimmune ophthalmic disease is a frequent challenge to rheumatologists from both a diagnostic and therapeutic perspective. Approved therapies are limited and have only been infrequently or comfortably utilized by rheumatologists and autoimmune ophthalmologists.
A EULAR task force has updated its 2009 recommendations for the management of anti-neutrophil cytoplasmic antibody associated vasculitis.
Tocilizumab is currently listed as a Category "C" pregnancy risk based on limited pre-clinical (animal) data that was negative.
Since the introduction of TNF inhibitors nearly 20 years ago, concerns over a potential associated cancer risk have abounded. The recent ACR RA treatment guidelines have addressed this recently, stating that patients with any solid tumor cancer or risk thereof should be treated as if they ha
Researchers from Bristol, UK have published a Cochrane review studying the effects of biologic therapies on fatigue.
Dr. Cush reviews highlights published this week at RheumNow.com.
The EULAR Annual European Congress of Rheumatology meeting was held in London from June 8-11, 2016 and was well attended by thousands. This year’s meeting had over 2,000 poster displays, and the EULAR 2016 Congress presented new recommendations on the management of rheumatoid arthritis, spondyloarthritis, and fibromyalgia.
Dr. Jack Cush reviews the news, reports and highlights from EULAR and the last 2 weeks from RheumNow.com.
The combined analysis of 130,315 rheumatoid arthritis patients from 11 European registries did not reveal an association between invasive (malignant) melanoma and the use of biologic therapies.
Blocking the type 1 interferon receptor with the monoclonal antibody anifrolumab shows promise as a treatment for moderate-to-severe systemic lupus erythematosus (SLE), according to a phase IIb study presented here.
No increased incidence of inflammatory bowel disease has been seen among patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab (Cosentyx) in the clinical trial programs for this interleukin (IL)-17A inhibitor, a researcher reported here.
Lancet has published the results of the U-ACT-early study assessing the efficacy of monotherapy versus combination therapy using an interleukin-6 receptor-blocking monoclonal antibody, tocilizumab, in patients with rheumatoid arthritis.
The NEJM today published the results of two phase-3 trials (UNCOVER-2 and UNCOVER-3) demonstrating the efficacy of ixekizumab (a monoclonal antibody against interleukin-17A) in the treatment of moderate-to-severe psoriasis.
The results of the PRAIRI study were presented today at EULAR 2016 in London. These early findings suggest that individuals "at-risk" to develop rheumatoid arthritis (RA) may benefit from a short course of intravenously rituximab therapy.
Desiree van der Heidje, MD, PhD presented the results of a 16-week, phase II, dose-ranging study of tofacitinib (TOFA) in patients with active ankylosing spondylitis.
The GiACTA study has published its top line results demonstrating the efficacy of adding tocilizumab (TCZ) to steroid-tapered therapy in patients with giant cell arteritis (GCA).
In April and May 2016, RheumNow sent 82 tweets regarding news, research and teaching points that strongly impacted the rheumatology community and resulted in a reach of 203,500 impressions, with 136 mentions, and over 6378 visits to RheumNow.com. Here are the top tweets from April and May.
This week's highlights from RheumNow.com include:
Gastrointestinal perforations (GIP) are not historically believed to be a common or uncommon complication. Hence, when this was noted in the tocilizumab (TCZ) and tofacitinib (TOFA) developmental trials, it was a curious if not perplexing finding.
